Log in
Enquire now
‌

US Patent 10973826 Antibody conjugates comprising toll-like receptor agonist

Patent 10973826 was granted and assigned to Novartis on April, 2021 by the United States Patent and Trademark Office.

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Current Assignee
Novartis
Novartis
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
109738260
Patent Inventor Names
Tom Yao-Hsiang Wu0
Xing Wang0
Alex Cortez0
Bernhard Hubert Geierstanger0
Shailaja Kasibhatla0
Tetsuo Uno0
Timothy Z. Hoffman0
Date of Patent
April 13, 2021
0
Patent Application Number
153332850
Date Filed
October 25, 2016
0
Patent Citations Received
‌
US Patent 11459399 Pharmaceutical compositions of a HER2/neu antibody and use of the same
‌
US Patent 11547761 Antibody adjuvant conjugates
‌
US Patent 11596695 Specific sites for modifying antibodies to make immunoconjugates
‌
US Patent 11400164 Immunoconjugates targeting HER2
Patent Primary Examiner
‌
Karen A. Canella
0
Patent abstract

Provided herein are antibody conjugates comprising toll-like receptor agonists and the use of such conjugates for the treatment of cancer. In some embodiments, the conjugates comprise anti-HER2 antibodies.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 10973826 Antibody conjugates comprising toll-like receptor agonist

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.